BioSpace News Archive

FDA Advisory Committee Scheduled to Review Lipocin

ZIOPHARM Jumps as Brain Cancer Drug Drug Helped Patients Live More Than a Year in Phase I Trial

New data presented shows median overall survival (mOS) of 12.5 months has been sustained for patients treated with Ad-RTS-hIL-12 plus 20mg of veledimex (n=15) at a longer mean follow-up time of 11.1 months as of October 18, 2017.

November 20, 2017

·

10 min read

Business

Cerveau Technologies and Enigma Biomedical Group Sign Research Agreement with Centre for Addiction and Mental Health (CAMH), Toronto

These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography scans for assessing the status and progression of neurofibrillary tangles in the brain.

November 20, 2017

·

2 min read

METTLER TOLEDO’s Limited-Edition 2018 Lab Calendar Provides Content to Help Refine Lab Practices

METTLER TOLEDO is pleased to announce the publication of its new, limited-edition lab calendar for 2018.

November 20, 2017

·

1 min read

Business

TESARO’s Mary Lynne Hedley and Lonnie Moulder Named EY National Entrepreneurs of the Year

They were also recognized as the National Award Winners in the Life Sciences category.

November 20, 2017

·

2 min read

Business

Shire to Appoint Thomas Dittrich as CFO and Member of the Board of Directors

Thomas will assume his roles at Shire in early 2018 following a transition period from his current employer.

November 20, 2017

·

2 min read

Business

Emerald Health Therapeutics Appoints Robert C. Hill, CPA, CA as Chief Financial Officer and Promotes Cheryl Evans, CPA, CA to Vice President Finance

Together Mr. Hill and Ms. Evans will be responsible for leading Emerald’s financial operations and organizational functions to facilitate the significant anticipated expansion of the Company’s business.

November 20, 2017

·

5 min read

AxoGen Advances its Platform for Nerve Repair at Annual Analyst and Investor Day

Additionally, the company will announce its newest application in breast reconstruction neurotization and outline its continued effort to evaluate expansions of the company’s portfolio of products in the surgical management of pain.

November 20, 2017

·

8 min read

Policy

TESARO Announces European Commission Approval of ZEJULA for Women With Recurrent Ovarian Cancer

ZEJULA was approved by the FDA on March 27, 2017 and is marketed by TESARO in the United States.

November 20, 2017

·

13 min read

Drug Development

Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia

Drug candidates with Fast Track designation may also qualify for priority review to expedite the FDA review process, if relevant criteria are met.